Cassiopea announces EUR 23.25 million capital increase by way of rights offering through the issuance of 750,000 shares at an offer price of EUR 31.00 per share
Cassiopea S.p.A., a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announces a capital increase by way of a rights offering to existing shareholders.